The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug Zepbound for obstructive sleep apnea, reported Annika Kim Constantino. Medicare Part D plans can cover obesity drugs if they are used for an additional medically accepted purpose approved by the FDA, which “opens the door for broader coverage of and access to Zepbound,” the report added. Other companies that offer treatments for sleep apnea include ResMed (RMD) and Inspire Medical (INSP).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- LLY, ABT, or ISRG: Which “Strong Buy” Healthcare Stock Could Deliver the Best Returns in 2025?
- Eli Lilly call volume above normal and directionally bullish
- The UK Approves Amgen’s (AMGN) Tarlatamab to Treat Small Cell Lung Cancer
- 5 Best Growth Stocks with Over 10% Upside Potential in 2025
- Why Elon Musk Prefers Eli Lilly’s (LLY) Mounjaro over Novo Nordisk’s Ozempic